BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $18,344,000 | -14.0% | 154,706 | 0.0% | 0.26% | -10.2% |
| Q4 2021 | $21,321,000 | -0.8% | 154,706 | 0.0% | 0.29% | +2.1% |
| Q3 2021 | $21,491,000 | +43.1% | 154,706 | 0.0% | 0.29% | +30.9% |
| Q2 2021 | $15,018,000 | +42.0% | 154,706 | 0.0% | 0.22% | +50.7% |
| Q1 2021 | $10,574,000 | -20.3% | 154,706 | 0.0% | 0.15% | -23.2% |
| Q4 2020 | $13,261,000 | -48.1% | 154,706 | -60.6% | 0.19% | -58.7% |
| Q3 2020 | $25,546,000 | -34.9% | 392,956 | -26.8% | 0.46% | -36.6% |
| Q2 2020 | $39,225,000 | +4.5% | 536,530 | -26.4% | 0.72% | -18.3% |
| Q1 2019 | $37,531,000 | +10.1% | 729,178 | -20.9% | 0.89% | +9.5% |
| Q4 2018 | $34,078,000 | +30.8% | 921,536 | +32.8% | 0.81% | +37.3% |
| Q3 2018 | $26,063,000 | +70.5% | 694,104 | +79.5% | 0.59% | +65.3% |
| Q2 2018 | $15,283,000 | +47.8% | 386,724 | -3.6% | 0.36% | +57.3% |
| Q1 2018 | $10,339,000 | – | 401,322 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |